FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2292282954> ?p ?o ?g. }

• W2292282954 endingPage "21824" @default.
• W2292282954 startingPage "21812" @default.
• W2292282954 abstract "// Yu-Hung Huang 1, 2 , Weidan Peng 1 , Narumi Furuuchi 1 , James B. DuHadaway 1 , Masaya Jimbo 6 , Andrea Pirritano 3 , Charles J. Dunton 1, 3 , Gary S. Daum 4 , Benjamin E. Leiby 5, 7 , Jonathan R. Brody 6, 7 , Janet A. Sawicki 1, 7 1 Lankenau Institute for Medical Research, Wynnewood, PA 19086, USA 2 Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA 19129, USA 3 Main Line Gynecologic Oncology, Lankenau Medical Center, Wynnewood, PA 19096, USA 4 Main Line Health Laboratories, Lankenau Medical Center, Wynnewood, PA 19096, USA 5 Division of Biostatistics, Thomas Jefferson University, Philadelphia, PA 19107, USA 6 Department of Surgery, Thomas Jefferson University, Philadelphia, PA 19107, USA 7 Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA Correspondence to: Janet A. Sawicki, e-mail: sawickij@mlhs.org Keywords: HuR, ovarian cancer, gemcitabine, carboplatin, WEE1 Received: January 12, 2016      Accepted: February 21, 2016      Published: March 02, 2016 ABSTRACT This retrospective study aimed to investigate the role that an RNA-binding protein, HuR, plays in the response of high-grade serous ovarian tumors to chemotherapeutics. We immunohistochemically stained sections of 31 surgically-debulked chemo-naïve ovarian tumors for HuR and scored the degree of HuR cytoplasmic staining. We found no correlation between HuR intracellular localization in tumor sections and progression free survival (PFS) of these patients, 29 of whom underwent second-line gemcitabine/platin combination therapy for recurrent disease. Ribonucleoprotein immunoprecipitation (RNP-IP) analysis of ovarian cancer cells in culture showed that cytoplasmic HuR increases deoxycytidine kinase (dCK), a metabolic enzyme that activates gemcitabine. The effects of carboplatin treatment on HuR and WEE1 (a mitotic inhibitor) expression, and on cell cycle kinetics, were also examined. Treatment of ovarian cancer cells with carboplatin results in increased HuR cytoplasmic expression and elevated WEE1 expression, arresting cell cycle G2/M transition. This may explain why HuR cytoplasmic localization in chemo-naïve tumors is not predictive of therapeutic response and PFS following second-line gemcitabine/platin combination therapy. These results suggest treatment of recurrent ovarian tumors with a combination of gemcitabine, carboplatin, and a WEE1 inhibitor may be potentially advantageous as compared to current clinical practices." @default.
• W2292282954 created "2016-06-24" @default.
• W2292282954 creator A5011756812 @default.
• W2292282954 creator A5019131703 @default.
• W2292282954 creator A5020290170 @default.
• W2292282954 creator A5038170197 @default.
• W2292282954 creator A5042291174 @default.
• W2292282954 creator A5075191661 @default.
• W2292282954 creator A5076631541 @default.
• W2292282954 creator A5078078975 @default.
• W2292282954 creator A5079398934 @default.
• W2292282954 creator A5084603346 @default.
• W2292282954 creator A5090373716 @default.
• W2292282954 date "2016-03-02" @default.
• W2292282954 modified "2023-10-10" @default.
• W2292282954 title "Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy" @default.
• W2292282954 cites W1500000190 @default.
• W2292282954 cites W1905518110 @default.
• W2292282954 cites W1978521302 @default.
• W2292282954 cites W1982079938 @default.
• W2292282954 cites W1982630848 @default.
• W2292282954 cites W1984568232 @default.
• W2292282954 cites W2015437489 @default.
• W2292282954 cites W2019378544 @default.
• W2292282954 cites W2019563964 @default.
• W2292282954 cites W2028495676 @default.
• W2292282954 cites W2038413819 @default.
• W2292282954 cites W2048254997 @default.
• W2292282954 cites W2058691182 @default.
• W2292282954 cites W2073427046 @default.
• W2292282954 cites W2075711878 @default.
• W2292282954 cites W2083123268 @default.
• W2292282954 cites W2089913183 @default.
• W2292282954 cites W2096293110 @default.
• W2292282954 cites W2104998982 @default.
• W2292282954 cites W2108648120 @default.
• W2292282954 cites W2111222453 @default.
• W2292282954 cites W2116130818 @default.
• W2292282954 cites W2117569814 @default.
• W2292282954 cites W2118202340 @default.
• W2292282954 cites W2121140284 @default.
• W2292282954 cites W2127243900 @default.
• W2292282954 cites W2130287530 @default.
• W2292282954 cites W2132919001 @default.
• W2292282954 cites W2135070076 @default.
• W2292282954 cites W2158836915 @default.
• W2292282954 cites W2167943497 @default.
• W2292282954 cites W2285541813 @default.
• W2292282954 cites W2411875523 @default.
• W2292282954 cites W2413697377 @default.
• W2292282954 doi "https://doi.org/10.18632/oncotarget.7840" @default.
• W2292282954 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5008325" @default.
• W2292282954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26943573" @default.
• W2292282954 hasPublicationYear "2016" @default.
• W2292282954 type Work @default.
• W2292282954 sameAs 2292282954 @default.
• W2292282954 citedByCount "7" @default.
• W2292282954 countsByYear W22922829542016 @default.
• W2292282954 countsByYear W22922829542018 @default.
• W2292282954 countsByYear W22922829542021 @default.
• W2292282954 countsByYear W22922829542023 @default.
• W2292282954 crossrefType "journal-article" @default.
• W2292282954 hasAuthorship W2292282954A5011756812 @default.
• W2292282954 hasAuthorship W2292282954A5019131703 @default.
• W2292282954 hasAuthorship W2292282954A5020290170 @default.
• W2292282954 hasAuthorship W2292282954A5038170197 @default.
• W2292282954 hasAuthorship W2292282954A5042291174 @default.
• W2292282954 hasAuthorship W2292282954A5075191661 @default.
• W2292282954 hasAuthorship W2292282954A5076631541 @default.
• W2292282954 hasAuthorship W2292282954A5078078975 @default.
• W2292282954 hasAuthorship W2292282954A5079398934 @default.
• W2292282954 hasAuthorship W2292282954A5084603346 @default.
• W2292282954 hasAuthorship W2292282954A5090373716 @default.
• W2292282954 hasBestOaLocation W22922829541 @default.
• W2292282954 hasConcept C121608353 @default.
• W2292282954 hasConcept C126322002 @default.
• W2292282954 hasConcept C143998085 @default.
• W2292282954 hasConcept C2776694085 @default.
• W2292282954 hasConcept C2778239845 @default.
• W2292282954 hasConcept C2780258809 @default.
• W2292282954 hasConcept C2780427987 @default.
• W2292282954 hasConcept C2780435969 @default.
• W2292282954 hasConcept C2781451048 @default.
• W2292282954 hasConcept C29456083 @default.
• W2292282954 hasConcept C502942594 @default.
• W2292282954 hasConcept C71924100 @default.
• W2292282954 hasConceptScore W2292282954C121608353 @default.
• W2292282954 hasConceptScore W2292282954C126322002 @default.
• W2292282954 hasConceptScore W2292282954C143998085 @default.
• W2292282954 hasConceptScore W2292282954C2776694085 @default.
• W2292282954 hasConceptScore W2292282954C2778239845 @default.
• W2292282954 hasConceptScore W2292282954C2780258809 @default.
• W2292282954 hasConceptScore W2292282954C2780427987 @default.
• W2292282954 hasConceptScore W2292282954C2780435969 @default.
• W2292282954 hasConceptScore W2292282954C2781451048 @default.
• W2292282954 hasConceptScore W2292282954C29456083 @default.
• W2292282954 hasConceptScore W2292282954C502942594 @default.
• W2292282954 hasConceptScore W2292282954C71924100 @default.

• next